David R. Bauer
Lawyers
Filters
Editas Medicine $231 million stock offering
We advised the joint book-running managers in connection with the equity offering
Affimed $115 million offering of shares
We advised the underwriters on the public equity offering
Generation Bio $225.4 million stock offering
We advised the underwriters on the public equity offering
Gracell Biotechnologies $209 million IPO and Nasdaq listing
We advised the underwriters on the IPO of ADSs
NGM Biopharmaceuticals $125 million follow-on offering
We advised the joint book-running managers on the public equity offering
Gamida Cell $75 million follow-on offering
Davis Polk advised the representatives of the underwriters in connection with the $75 million SEC-registered follow-on offering of 9,343,750 ordinary shares of Gamida Cell Ltd, which…
BeiGene $340 million secondary offering
Davis Polk advised the underwriter in connection with the $340 million SEC-registered offering of 1,511,546 American depositary shares of BeiGene, Ltd. by certain existing ADS holders. The…
RAPT Therapeutics $100 million at-the-market offering
Davis Polk advised the sales agents on the SEC-registered at-the-market offering by RAPT Therapeutics, Inc. of its common stock for up to an aggregate amount of $100 million.
RAPT…
Maravai LifeSciences Holdings $1.863 billion IPO
Davis Polk advised the representatives of the several underwriters in connection with the initial public offering of 69,000,000 shares of Class A common stock of Maravai LifeSciences…
Stoke Therapeutics $112 million follow-on offering
Davis Polk advised the representatives of the underwriters in connection with the $112 million public offering of 2,500,000 shares of common stock of Stoke Therapeutics, Inc., which…